ClinicalTrials.gg
Active, not recruitingNCT03419234Updated Oct 6, 2026Results posted

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

A Phase 2 interventional study of Abiraterone Acetate and Androgen deprivation therapy in Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma in the Soft Tissue, sponsored by ECOG-ACRIN Cancer Research Group. Active, not recruiting at 672 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by ECOG-ACRIN Cancer Research Group · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
223
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.

Enrollment
9th of 46
223 · median 60
Started
2018
with 1 other
Phase 2
28 of 46
5 open now
Registered
36th of 46
by date

Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one is the 9th largest by enrollment, is one of 2 that started in 2018, is one of 28 in phase 2, and was the 36th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About cabazitaxel

cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing cabazitaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using abiraterone acetate and antiandrogen therapy may fight prostate cancer by lowering and/or blocking the use of androgens by the tumor cells. Drugs used in chemotherapy, such as cabazitaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving abiraterone acetate and antiandrogen therapy with or without cabazitaxel and prednisone may help kill more tumor cells.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with castration-resistant prostate cancer (CRPC) that have previously received docetaxel and androgen deprivation therapy (ADT) for hormone-sensitive prostate cancer (HSPC) can improve progression-free survival (PFS) compared to abiraterone acetate alone.

SECONDARY OBJECTIVES:

I. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel and ADT for HSPC can increase the percentage of change in prostate-specific antigen (PSA) from baseline to week 12 of treatment as well as the maximum decline in PSA that occurs at any point after treatment compared to abiraterone acetate alone.

II. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel for HSPC can prolong time to PSA progression compared to abiraterone acetate alone.

III. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel for HSPC can improve radiographic response (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) compared to abiraterone acetate alone.

IV. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel and ADT for HSPC can prolong the overall survival (OS) compared to abiraterone acetate alone.

V. To assess safety and tolerability of the combination of 6 cycles of cabazitaxel and abiraterone acetate.

TERTIARY OBJECTIVES:

I. To examine whether patients with circulating tumor cells (CTCs) positive for AR-V7 at baseline have a longer radiographic or clinical PFS to the combination of cabazitaxel and abiraterone acetate vs. abiraterone acetate alone.

II. To examine whether the addition of cabazitaxel to abiraterone acetate can change the AR-V7 status of patients who are positive at study entry.

III. To examine whether the addition of cabazitaxel to abiraterone acetate has any impact on future development of AR-V7 positivity at the time of disease progression.

IV. To assess if the changes in total tumor burden from baseline to week 12 as assessed with sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (CT) will differ between two arms.

V. To correlate total tumor burden at the baseline as assessed with NaF PET/CT with the PFS.

VI. To correlate heterogeneity of response from baseline to week 12 as assessed with NaF PET/CT with the PFS.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive abiraterone acetate orally (PO) once daily (QD) on days 1-21, prednisone PO twice daily (BID) on days 1-21. Courses of abiraterone acetate and prednisone repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients receive cabazitaxel intravenously (IV) over 1 hour on day 1, and treatment with cabazitaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with either luteinizing hormone-releasing hormone (LHRH) agonist or antagonist, or surgical castration with bilateral orchiectomy.

ARM B: Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.

After completion of study treatment, patients are followed up every 3 or 6 months and then annually for up to 5 years.

03

Conditions studied

  • Castration Levels of Testosterone
  • Castration-Resistant Prostate Carcinoma
  • Metastatic Prostate Carcinoma in the Soft Tissue
  • Prostate Carcinoma Metastatic in the Bone
  • Stage IV Prostate Adenocarcinoma AJCC v7

Browse trials for

Keywords

  • prostate cancer
  • Castration-Resistant Prostate Cancer
  • Cabazitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate)
  • Previous chemotherapy with at least 3 cycles of docetaxel for hormone-sensitive prostate cancer
  • Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (CT/magnetic resonance imaging [MRI] of abdomen/pelvis, bone scintigraphy or NaF PET/CT)
  • Ability to swallow abiraterone acetate tablets as a whole
  • All patients must be receiving standard of care androgen deprivation treatment (surgical castration versus LHRH agonist or antagonist treatment); subjects receiving LHRH agonist or antagonist must continue treatment throughout the time on this study
  • Patients must have castrate serum level of testosterone of \< 50 ng/dL (\< 1.73 nmol/L)
  • Patients must have progressive disease while receiving androgen deprivation therapy defined by any one of the following as per the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria for PSA, or non-measurable (bone) disease during treatment with ADT:

    • PSA: At least two consecutive rises in serum PSA, obtained at a minimum of 1-week intervals, with the final value >= 1.0 ng/mL, confirmed \<=4 weeks prior to randomization
    • Measurable disease (by 1.1): > 20% increase in the sum of the longest diameters of all measurable lesions or the development of new measurable lesions; the short axis of a target lymph node must be more than 15 mm to be assessed for change in size
    • Non-measurable (bone) disease: The appearance of two or more new areas of uptake on bone scan (or NaF PET/CT) consistent with metastatic disease compared to previous imaging during castration therapy; the increased uptake of pre-existing lesions on bone scan will not be taken to constitute progression, and ambiguous results must be confirmed by other imaging modalities (e.g. X-ray, CT or MRI). Clinical decisions about response or progression will be based on CT and bone scans.
  • Patients may or may not have been treated previously with a nonsteroidal antiandrogen, such as flutamide, bicalutamide or nilutamide; for patients previously treated with an antiandrogen, they must be off treatment for at least 4 weeks (for flutamide) or 6 weeks (for bicalutamide or nilutamide) prior to registration and must have shown PSA progression after discontinuing the anti-androgen
  • Patients must have an (ECOG) performance status of 0, 1, or 2
  • (ANC) >= 1500/mm\^3
  • (HgB) >= 9.0 gr/dL
  • >= 100,000/mm\^3
  • Creatinine \< 2.0 mg/dL
  • Patients must be informed of the experimental nature of the study and its potential risks, and must sign an Institutional Review Board (IRB)-approved written form indicating such an understanding
  • Patients with resected or irradiated or those treated with stereotactic radiation therapy are eligible to enroll, provided that they do not require treatment with that exceeds 10 mg of prednisone daily or equivalent
  • Sexually active males must use an accepted and effective method of double barrier or abstain from sexual intercourse for the duration of their participation in the study and for 26 weeks after the last dose of study drug
  • NaF PET/CT OPTIONAL SUB-STUDY ELIGIBILITY CRITERIA

    • Ability to lie still for imaging
    • Weight =\< 300 lbs (pounds)
    • Metastatic disease confined predominantly to the bones

Exclusion criteria

Exclusion Criteria:

  • Any prior chemotherapy or androgen receptor (AR)-directed therapy for CRPC, (e.g. docetaxel, cabazitaxel, mitoxantrone, abiraterone acetate, ketoconazole, or enzalutamide); previous treatment with radium-223 or sipuleucel-T is allowed
  • Pure small cell or other variant (non-adenocarcinoma) prostate cancer histology for which treatment with abiraterone would not be considered appropriate
  • Patients may not be receiving other therapeutic agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy; concurrent treatment with agents to prevent skeletal-related events (such as zoledronic acid or denosumab) will be allowed as long as it was initiated prior to study entry or there are plans to initiate it after cycle 2 day 1.
  • Any medical condition for which prednisone () is
  • Total > (ULN) (NOTE: in subjects with Gilbert's syndrome, if total bilirubin is > ULN, measure direct and indirect bilirubin and if direct bilirubin is within normal range, subject may be eligible)
  • Alanine () or aspartate (AST) aminotransferase > 1.5 x ULN
  • Active infection requiring treatment with antibiotics
  • History of adrenal insufficiency or hypoaldosteronism
  • Myocardial infarction or arterial thrombotic event within 6 months of randomization, heart failure of class II or higher, uncontrolled angina, severe uncontrolled ventricular arrhythmia
  • External beam radiation therapy within 2 weeks of registration
  • Prior history of allergic reactions to G-CSF
  • Prior history of allergic reactions to docetaxel and/or to medications formulated with polysorbate 80
  • History of active ; patients with a history of cancer that has been adequately treated and are free of disease recurrence for 3 years or more are allowed to participate; patients with non-melanoma skin cancers or carcinoma in situ of the bladder that have been adequately excised are eligible to participate
  • of \< 12 months at screening
  • Grade >= 2 neuropathy
  • Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg). Patients with a history of hypertension are allowed to enroll provided blood pressure is controlled with anti-hypertensive treatment
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    Arm A (abiraterone acetate, prednisone, cabazitaxel)

    Patients receive abiraterone acetate PO QD on days 1-21, prednisone PO BID on days 1-21. Courses of abiraterone acetate and prednisone repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients receive cabazitaxel IV over 1 hour on day 1, and treatment with cabazitaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.

    Drug: Abiraterone Acetate · Drug: Androgen deprivation therapy · Drug: Cabazitaxel · Drug: Prednisone

  • Active comparator
    Arm B (abiraterone acetate, prednisone)

    Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.

    Drug: Abiraterone Acetate · Drug: Androgen deprivation therapy · Drug: Prednisone

Interventions

  • Given PO

    Also known as: Zytiga

  • DrugAndrogen deprivation therapy

    Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist or surgical castration with bilateral orchiectomy.

  • Given IV

    Also known as: Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258

  • Given PO

    Also known as: Deltasone, Orasone, Medicorten, Panasol-S, Liquid-Pred

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment.

    Time frame: Assessed every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years

Secondary outcomes

  1. Percent Change in PSA From Baseline to 12 Weeks

    PSA was assessed at baseline and 12 weeks. Percent change in PSA from baseline to 12 weeks is calculated as follows: ((PSA at 12 weeks - baseline PSA)/baseline PSA) x 100

    Time frame: Assessed at baseline and 12 weeks

  2. Maximum Percent Change in PSA From Baseline While on Treatment

    Maximum percent change in PSA from baseline while on treatment was calculated as follows: ((PSA nadir while on treatment - baseline PSA)/baseline PSA) x 100

    Time frame: Assessed at baseline, every 3 weeks for 18 weeks, then every 6 weeks until treatment discontinuation, up to 5 years

  3. Time to PSA Progression

    Time to PSA progression was defined as the time from randomization to PSA progression or date of last PSA assessment. Patients who experienced radiographic progression without documented PSA progression were counted as having an event.

    Time frame: Assessed at baseline, every 3 weeks for 18 weeks, then every 6 weeks until treatment discontinuation, up to 5 years

  4. Proportion of Patients With Radiographic Response

    Radiographic response was evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and was defined as either complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. All (non-target) lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Assessed every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years

  5. Overall Survival (OS)

    Overall survival was defined as the time from randomization until death or date last known alive.

    Time frame: Assessed every 3 month is patient is < 2 years from study entry, every 6 months if patient is 2-3 years from study entry, and then annually for up to year 5

Other outcomes

  1. PFS Among Patients With Circulating Tumor Cells (CTCs) Positive for Androgen-receptor Splice Variant 7 Messenger RNA (AR-V7) at Baseline

    PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. AR-V7 was assessed at baseline.

    Time frame: Assessed at baseline, every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years

  2. Androgen-Receptor Splice Variant 7 Messenger RNA (AR-V7) Status

    The presence of AR-V7 in circulating tumor cells was assessed at baseline and Cycle 5 Day 1.

    Time frame: Assessed at baseline and Cycle 5 Day 1

  3. Development of AR-V7 Positivity at the Time of Disease Progression

    The presence of AR-V7 in circulating tumor cells was assessed at baseline and disease progression.

    Time frame: Assessed at baseline and disease progression

  4. Changes in Total Tumor Burden From Baseline to Week 12 as Assessed With NaF PET/CT

    Total tumor burden was assessed by NaF PET/CT at baseline and 12 weeks. The changes in total tumor burden will be compared between the two arms.

    Time frame: Assessed at baseline and 12 weeks

  5. Association Between PFS and Total Tumor Burden at the Baseline as Assessed With NaF PET/CT

    PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. The association between PFS and total tumor burden at baseline as assessed with NaF PET/CT will be evaluated.

    Time frame: Assessed at baseline, every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years

  6. The Association Between PFS and the Heterogeneity of Response From Baseline to Week 12 as Assessed With NaF PET/CT

    PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. The association between PFS and the heterogeneity of response from baseline to week 12 as assessed with NaF PET/CT will be evaluated.

    Time frame: Assessed at baseline, 12 weeks, every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years

07

Results

Posted Jan 8, 2026

Participant flow

This study was activated on February 8, 2018 and closed to accrual on March 26, 2021, after accrual of 223 patients.

Participant flow — Overall Study
MilestoneArm A (Abiraterone Acetate, Prednisone, Cabazitaxel)Arm B (Abiraterone Acetate, Prednisone)
Started111112
Patients who received protocol therapy109108
Patients who started protocol therapy and had both baseline psa as well as 12-week psa available10093
Completed00
Not completed111112
Withdrew: Disease progression3736
Withdrew: Adverse event69
Withdrew: Withdrawal by subject97
Withdrew: Death51
Withdrew: Alternative therapy42
Withdrew: Psa progression810
Withdrew: Rising psa and bone issues32
Withdrew: Clinical deterioration/clinical progression/symptomatic progression1016
Withdrew: Physician decision1211
Withdrew: Second malignancy10
Withdrew: Insurance status change/patient could not afford21
Withdrew: Non-compliance13
Withdrew: Mistakenly off treatment10
Withdrew: Transition to hospice10
Withdrew: Still on treatment98
Withdrew: Never received protocol therapy24
Withdrew: Other complicating disease01
Withdrew: Patient switched from prednisone to another steroid01

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment.

Time frame:
Assessed every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years
Reported as:
Median · months
Progression-free Survival (PFS)
monthsArm A (Abiraterone Acetate, Prednisone, Cabazitaxel)Arm B (Abiraterone Acetate, Prednisone)
Progression-free Survival (PFS)14.9 (9.9 to 18.6)9.9 (7.0 to 12.6)
Statistical analysis
  • Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) vs Arm B (Abiraterone Acetate, Prednisone) · Log Rank · p = 0.049Stratified log rank test
SecondaryPercent Change in PSA From Baseline to 12 Weeks

PSA was assessed at baseline and 12 weeks. Percent change in PSA from baseline to 12 weeks is calculated as follows: ((PSA at 12 weeks - baseline PSA)/baseline PSA) x 100

Time frame:
Assessed at baseline and 12 weeks
Reported as:
Median · percentage of change in PSA
Percent Change in PSA From Baseline to 12 Weeks
percentage of change in PSAArm A (Abiraterone Acetate, Prednisone, Cabazitaxel)Arm B (Abiraterone Acetate, Prednisone)
Percent Change in PSA From Baseline to 12 Weeks-87.5 (-94.9 to -52.1)-65.9 (-91.3 to -16.1)
SecondaryMaximum Percent Change in PSA From Baseline While on Treatment

Maximum percent change in PSA from baseline while on treatment was calculated as follows: ((PSA nadir while on treatment - baseline PSA)/baseline PSA) x 100

Time frame:
Assessed at baseline, every 3 weeks for 18 weeks, then every 6 weeks until treatment discontinuation, up to 5 years
Reported as:
Median · percentage of change in PSA
Maximum Percent Change in PSA From Baseline While on Treatment
percentage of change in PSAArm A (Abiraterone Acetate, Prednisone, Cabazitaxel)Arm B (Abiraterone Acetate, Prednisone)
Maximum Percent Change in PSA From Baseline While on Treatment-94.0 (-98.1 to -65.8)-67.7 (-94.8 to -15.5)
SecondaryTime to PSA Progression

Time to PSA progression was defined as the time from randomization to PSA progression or date of last PSA assessment. Patients who experienced radiographic progression without documented PSA progression were counted as having an event.

Time frame:
Assessed at baseline, every 3 weeks for 18 weeks, then every 6 weeks until treatment discontinuation, up to 5 years
Reported as:
Median · months
Time to PSA Progression
monthsArm A (Abiraterone Acetate, Prednisone, Cabazitaxel)Arm B (Abiraterone Acetate, Prednisone)
Time to PSA Progression10.0 (8.5 to 13.5)6.1 (4.4 to 8.0)
SecondaryProportion of Patients With Radiographic Response

Radiographic response was evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and was defined as either complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. All (non-target) lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Assessed every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years
Reported as:
Number · Proportion of participants
Proportion of Patients With Radiographic Response
Proportion of participantsArm A (Abiraterone Acetate, Prednisone, Cabazitaxel)Arm B (Abiraterone Acetate, Prednisone)
Proportion of Patients With Radiographic Response0.117 (0.064 to 0.192)0.080 (0.037 to 0.147)
SecondaryOverall Survival (OS)

Overall survival was defined as the time from randomization until death or date last known alive.

Time frame:
Assessed every 3 month is patient is < 2 years from study entry, every 6 months if patient is 2-3 years from study entry, and then annually for up to year 5
Reported as:
Median · months
Overall Survival (OS)
monthsArm A (Abiraterone Acetate, Prednisone, Cabazitaxel)Arm B (Abiraterone Acetate, Prednisone)
Overall Survival (OS)25.0 (20.6 to 32.5)26.9 (19.6 to 29.4)
Other pre-specifiedPFS Among Patients With Circulating Tumor Cells (CTCs) Positive for Androgen-receptor Splice Variant 7 Messenger RNA (AR-V7) at Baseline

PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. AR-V7 was assessed at baseline.

Time frame:
Assessed at baseline, every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years

Results for this outcome have not been posted.

Other pre-specifiedAndrogen-Receptor Splice Variant 7 Messenger RNA (AR-V7) Status

The presence of AR-V7 in circulating tumor cells was assessed at baseline and Cycle 5 Day 1.

Time frame:
Assessed at baseline and Cycle 5 Day 1

Results for this outcome have not been posted.

Other pre-specifiedDevelopment of AR-V7 Positivity at the Time of Disease Progression

The presence of AR-V7 in circulating tumor cells was assessed at baseline and disease progression.

Time frame:
Assessed at baseline and disease progression

Results for this outcome have not been posted.

Other pre-specifiedChanges in Total Tumor Burden From Baseline to Week 12 as Assessed With NaF PET/CT

Total tumor burden was assessed by NaF PET/CT at baseline and 12 weeks. The changes in total tumor burden will be compared between the two arms.

Time frame:
Assessed at baseline and 12 weeks

Results for this outcome have not been posted.

Other pre-specifiedAssociation Between PFS and Total Tumor Burden at the Baseline as Assessed With NaF PET/CT

PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. The association between PFS and total tumor burden at baseline as assessed with NaF PET/CT will be evaluated.

Time frame:
Assessed at baseline, every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years

Results for this outcome have not been posted.

Other pre-specifiedThe Association Between PFS and the Heterogeneity of Response From Baseline to Week 12 as Assessed With NaF PET/CT

PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. The association between PFS and the heterogeneity of response from baseline to week 12 as assessed with NaF PET/CT will be evaluated.

Time frame:
Assessed at baseline, 12 weeks, every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years

Results for this outcome have not been posted.

Adverse events

Collected over Assessed every 3 weeks while on treatment and for 30 days after the end of treatment, up to 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel)80/111 (72.1%)46/109 (42.2%)101/109 (92.7%)
Arm B (Abiraterone Acetate, Prednisone)79/112 (70.5%)31/108 (28.7%)80/108 (74.1%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventArm A (Abiraterone Acetate, Prednisone, Cabazitaxel)Arm B (Abiraterone Acetate, Prednisone)
HypertensionVascular disorders11/10912/108
Neutrophil count decreasedInvestigations11/1090/108
White blood cell decreasedInvestigations9/1090/108
AnemiaBlood and lymphatic system disorders7/1091/108
FatigueGeneral disorders and administration site conditions6/1092/108
Alanine aminotransferase increasedInvestigations1/1095/108
Urinary tract infectionInfections and infestations5/1090/108
HypokalemiaMetabolism and nutrition disorders4/1094/108
DiarrheaGastrointestinal disorders4/1090/108
SepsisInfections and infestations4/1090/108
Most frequent other events
Showing 10 of 16
Most frequent other events
EventArm A (Abiraterone Acetate, Prednisone, Cabazitaxel)Arm B (Abiraterone Acetate, Prednisone)
FatigueGeneral disorders and administration site conditions78/10947/108
AnemiaBlood and lymphatic system disorders60/10930/108
DiarrheaGastrointestinal disorders37/1096/108
HypertensionVascular disorders37/10936/108
Edema limbsGeneral disorders and administration site conditions22/10913/108
HypokalemiaMetabolism and nutrition disorders19/10919/108
VomitingGastrointestinal disorders18/1094/108
Lymphocyte count decreasedInvestigations14/1093/108
ConstipationGastrointestinal disorders12/1098/108
DyspneaRespiratory, thoracic and mediastinal disorders12/1099/108

Baseline characteristics

All randomized patients were included in this analysis.

Age, Continuous
Age, Continuous(years)Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel)Arm B (Abiraterone Acetate, Prednisone)Total
Median63 (42 to 79)66 (41 to 80)64 (41 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel)Arm B (Abiraterone Acetate, Prednisone)Total
Female000
Male111112223
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel)Arm B (Abiraterone Acetate, Prednisone)Total
Hispanic or Latino5510
Not Hispanic or Latino104105209
Unknown or Not Reported224
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel)Arm B (Abiraterone Acetate, Prednisone)Total
American Indian or Alaska Native022
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American202242
White8481165
More than one race000
Unknown or Not Reported7512
08

Study locations

672 sites

Showing the first 100 of 672 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Jan 2024, 68 months.

Results were first posted in Jan 2026, 2 years after primary completion.

Of 610 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 86. This study's 68 months is above that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2018
First posted
Feb 1, 2018
StartActual
Apr 26, 2018
Primary completionActual
Jan 8, 2024
CompletionEst.
Apr 1, 2028
Results first posted
Jan 8, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03419234
Responsible party
Sponsor
First posted
Feb 1, 2018
Start date
Apr 26, 2018
Primary completion
Jan 8, 2024
Completion
Apr 1, 2028 (estimated)
Results posted
Jan 8, 2026
Last update
Oct 6, 2026

Study contacts

Christos Kyriakopoulos
principal investigator · ECOG-ACRIN Cancer Research Group

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabazitaxel

Start the discussion